AUSTEDOXR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of tardivedyskinesia.
Once-daily AUSTEDOXR® (deutetrabenazine) extended release tablets reduce uncontrollable TardiveDyskinesia (TD) body movements. See safety info including Boxed Warning.
Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the AustedoXR (extended-release) tablets are taken once daily. What is Tardivedyskinesia (TD) and chorea associated with Huntington’s disease
She added, “These data articulate patient experience and further validate clinical research showing how AUSTEDO or AUSTEDOXR can help people living with tardivedyskinesia improve their symptoms while maintaining their mental health, something we care deeply about in our mission at Teva to improve the lives of patients.”
The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardivedyskinesia were nasopharyngitis and insomnia.
Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardivedyskinesia. Austedo is the first VMAT2 inhibitor approved by the US Food and Drug Administration for adults with tardivedyskinesia. 3 It is not currently approved for pediatric patients. References 1.
Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardivedyskinesia and chorea caused by Huntington’s disease.
Teva Pharmaceuticals announced data from the ongoing real-world phase 4 study, coined IMPACT-TD Registry, evaluating the efficacy of deutetrabenazine (Austedo) tablets and its extended-release tablet formulation (AustedoXR) in patients with tardivedyskinesia (TD). Overall, the findings showed that both treatments are associated with reduced severity of involuntary movements and improvements ...
The FDA has approved AustedoXR in four new tablet strengths for adults diagnosed with tardivedyskinesia and chorea associated with Huntington’s disease, according to the manufacturer. In a ...
